Replaces Prod. #: ALX-270-067
H-8 inhibits PKA and PKG selectively over PKC and MLCK (IC50’s=1.2μM, 0.48μM, 15μM and 68μM respectively). It also inhibits myosin light chain kinase.
Product Details
| Formula: | C12H15N3O2S . 2HCl |
| |
| MW: | 338.3 |
| |
| CAS: | 84478-11-5 |
| |
| Purity: | ≥98% (TLC) |
| |
| Appearance: | White to off-white solid. |
| |
| Solubility: | Soluble in DMSO (25mg/ml) and ethanol/water (1:1, 25mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | +4°C |
| |
| Use/Stability: | Store, as supplied, at 0-4°C for up to 1 year. Store solutions at -20°C for up to 3 months. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Crystal structures of catalytic subunit of cAMP-dependent protein kinase in complex with isoquinolinesulfonyl protein kinase inhibitors H7, H8, and H89. Structural implications for selectivity.: R.A. Engh, et al.; J. Biol. Chem.
271, 26157 (1996),
Abstract;
Differential growth inhibition of isoquinolinesulfonamides H-8 and H-7 towards multidrug-resistant P388 murine leukaemia cells.: M. Ido, et al.; Br. J. Cancer
64, 1103 (1991),
Abstract;
Selective modulation of calcium-dependent myosin phosphorylation by novel protein kinase inhibitors, isoquinolinesulfonamide derivatives.: M. Hagiwara, et al.; Mol. Pharmacol.
32, 7 (1987),
Abstract;
Specific binding of a novel compound, N-[2-(methylamino)ethyl]-5-isoquinolinesulfonamide (H-8) to the active site of cAMP-dependent protein kinase.: M. Hagiwara, et al.; Mol. Pharmacol.
31, 523 (1987),
Abstract;
Naphthalenesulfonamides as calmodulin antagonists and protein kinase inhibitors.: M. Inagaki, et al.; Mol. Pharmacol.
29, 577 (1986),
Abstract;
Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C.: H. Hidaka, et al.; Biochemistry
23, 5036 (1984),
Abstract;
